mutations and complicated kar yotype. It follows a linear evolution from the CLL clone with the recurrent acquisition of CDKN2A??? "???????????????????????????????????????????????"102 On the flip side, quite a few groups are advocating for the incorporation of novel markers, such as a complex karyotype55 or epigenetic subsets, 27,28 into clinical o